Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bidimensional Early Intervention Strategy of Standard of Care Combined With Host Immunomodulation in Elderly Patients With Mild or Moderate COVID-19: A Multicentre, Randomized, Controlled, Adaptive Platform Study

NCT05855395 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT05855395
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05855395 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bidimensional Early Intervention Strategy of Standard of Care Combined With Host Immunomodulation in Elderly Patients With Mild or Moderate COVID-19: A Multicentre, Randomized, Controlled, Adaptive Platform Study
Lead sponsor
Huashan Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 26, 2023
Completion date
December 1, 2024
Enrollment
5,815 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19